Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Crispr Therapeutics

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Kiplinger

CRISPR Therapeutics Joins Rank Of Stocks With RS Ratings Over 90

CRISPR Therapeutics sees its Relative Strength Rating move into the elite 90-plus level.

Investors Business Daily

CRISPR Therapeutics Earns Relative Strength Rating Upgrade; Hits Key Threshold

A Relative Strength Rating upgrade for CRISPR Therapeutics shows improving technical performance.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks With Rising Relative Strength: CRISPR Therapeutics

CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

MarketBeat

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Benzinga

Crispr Stock Whipsaws As Wall Street Watches Its Gene-Editing Blockbuster Candidate

Crispr Therapeutics reported its first profit in 10 quarters on Wednesday, but CRSP stock whipsawed.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks

ARK Innovation, the flagship Cathie Wood ETF, is skidding in 2024 as the S&P 500 hits a record high. Blame Coinbase, Tesla and other big ARKK ETF holdings.

Investors Business Daily

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time.

Investors Business Daily

Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. But gene editing therapies aren’t without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.

Investors Business Daily

CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News

CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade

A Relative Strength Rating upgrade for CRISPR Therapeutics shows improving technical performance.

Investors Business Daily

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug

The FDA appears likely to approve Crispr's gene-editing approach to sickle cell disease, analysts said Wednesday as CRSP stock gapped higher.

Investors Business Daily

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment

Crispr is facing its make-or-break moment and, experts say, a pivotal decision in December could spark more than just beleaguered CRSP stock.

Investors Business Daily

Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months

The FDA could approve Crispr Therapeutics' gene-edited sickle cell treatment as early as December. In response, CRSP stock surged Friday.

Investors Business Daily

CRISPR Therapeutics Stock Joins Rank Of Stocks With RS Ratings Over 90

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

CRISPR Therapeutics Stock Sees Relative Strength Rating Rise To 89

A Relative Strength Rating upgrade for CRISPR Therapeutics shows improving technical performance.

Barchart

Markets Today: Stock Index Futures Climb on Dovish PPI Surprise

Morning Markets June S&P 500 futures (ESM2 3) this morning are up +0.21%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.37%. U.S. stock index futures this morning are moderately higher after U.S. Mar producer prices rose less than expected, easing inflation concerns. Also, weekly jobless claims rose...

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.